SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias sharp selloff is being tied by traders to fears that a Democratic sweep could bring tighter AI regulation or delay data-center projects, alongside broader doubts about AI spending and the sustainability of the chip rally. The community is divided between calling it an AI-bubble unwind and buying the dip on confidence in Nvidias long-term business.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff is being tied by traders to fears that the Democrats midterm gains could bring tighter AI rules and slow data-center investment, adding pressure to tech-heavy indexes. The community is split between seeing the drop as an overreaction and buying opportunity and expecting further losses amid uncertainty and an unwind in AI-related stocks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp tech-led selloff is being tied by traders to fears that the Democratic midterm sweep could bring tighter AI and data-center rules and slow infrastructure spending, with semiconductor weakness adding pressure. The community is split between seeing a deeper correction and AI-trade unwind ahead and viewing the drop as an overreaction or dip-buying opportunity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns sharp selloff is being tied by traders to fears that Democratic gains and calls for tighter AI regulation could slow data-center construction and weaken demand for AI-related chips and memory, amid a broader semiconductor and AI-trade unwind. The community is divided between viewing the drop as an overreaction and dip-buying opportunity because AI memory demand remains strong, and warning that weaker AI spending or a prolonged sector reset could bring further declines.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances quarterly results drew attention with record revenue growth, improved gross margins, and a longer cash runway, but the stock sold off despite the strong report. Traders debate whether broad biotech-market weakness and profit-taking drove the decline or whether concerns about Amtagvis sequential growth and the lung-cancer programs durability and 2027 filing timeline are weighing on sentiment.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp semiconductor and AI-stock selloff has drawn attention to AMD, with traders speculating that post-midterm calls for AI regulation could slow data-center construction, alongside broader concerns about AI spending. The drop contrasts with AMDs strong results and outlook; some traders call it an overreaction and buying opportunity, while others see lingering capex and valuation risks.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical-infrastructure stocks, with traders citing concerns about hyperscaler spending, AI valuations and the companys upcoming earnings outlook. Some see the decline as an oversold buying opportunity, while others fear more downside and question whether strong results would be enough to reverse the weak sentiment.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys quarterly results and outlookfeaturing its first GAAP profit since going public, accelerating Vector advertising growth, and upbeat forward guidanceare driving the rally. Traders are largely celebrating a potential turnaround, while some question whether shares can sustain gains and break through resistance.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff has hammered SOXL, with traders pointing to fears that political shifts could constrain AI and data-center investment, alongside broader worries that the AI trade is unwinding. The funds 3x daily leverage has magnified the drop; traders disagree on whether it marks capitulation and a buying opportunity or further downside ahead.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure as semiconductor traders reassess the AI buildout, weighing concerns that data-center restrictions and doubts about returns on heavy AI spending could slow chip demand. The community is split between fears that the AI trade is unraveling and calls that the selloff is an overreaction, with compute demand still intact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cash Dividend On The Way From Crown Holdings (CCK)

Looking at the universe of stocks we cover at Dividend Channel, on 11/5/26, Crown Holdings Inc (Symbol: CCK) will trade ex-dividend, for its quarterly dividend of $0.35, payable on 11/19/26. As a percentage of CCK's recent stock price of $121.16, this dividend works out to appr...

Why Crown Holdings (CCK) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Is Crown Holdings (CCK) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

CROWN HOLDINGS, INC. ELECTS WAYNE SMITH TO ITS BOARD OF DIRECTORS

CROWN HOLDINGS, INC. ELECTS WAYNE SMITH TO ITS BOARD OF DIRECTORS CROWN HOLDINGS, INC. ELECTS WAYNE SMITH TO ITS BOARD OF DIRECTORSPR NewswireTAMPA, Fla., Oct. 22, 2026 TAMPA, Fla., Oct. 22, 2026 /PRNewswire/ -- Crown Holdings, Inc. (NYSE: CCK) announced today that Wayne T. Smith has been elected...

CROWN HOLDINGS, INC. DECLARES QUARTERLY DIVIDEND

CROWN HOLDINGS, INC. DECLARES QUARTERLY DIVIDEND CROWN HOLDINGS, INC. DECLARES QUARTERLY DIVIDENDPR NewswireTAMPA, Fla., Oct. 22, 2026 TAMPA, Fla., Oct. 22, 2026 /PRNewswire/ -- Crown Holdings, Inc. (NYSE:CCK) announced today that its Board of Directors declared a cash dividend of $0.35 per share...

Crown (CCK) Upgraded to Buy: Here's What You Should Know

Crown (CCK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Industrial Products Stocks Lagging  AZZ (AZZ) This Year?

Here is how AZZ (AZZ) and Crown Holdings (CCK) have performed compared to their sector so far this year.

Crown Holdings Q3 2026 Earnings Call Transcript

Crown Holdings (NYSE:CCK) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...

Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line

Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day Line Nasdaq Jumps Past 1 Percent as VIX Swings While Dow Dips Below Its 50-Day LinePR NewswireVANCOUVER, BC, Oct. 19, 2026 VANCOUVER, BC, Oct. 19, 2026 /PRNewswire/ -- Stock Preachers News Commentary- Big tech drove a sharp...

Crown (CCK) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Crown (CCK) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

• Reported GAAP EPS of $2.39 up 6.70% YoY
• Reported revenue of $3.71B up 15.90% YoY
• Crown Holdings expects FY2026 adjusted diluted EPS of $8.35 to $8.45 and adjusted free cash flow of at least $950M after approximately $550M capital spending; Q4 adjusted diluted EPS is $1.63 to $1.73.

Crown Holdings segment income was $484M versus $490M as shipment contributions were offset by input cost inflation; adjusted free cash flow was $299M versus $500M, and supply-chain continuity remains a stated risk.

Crown Holdings reported global beverage can shipments advanced more than 6%, expansion projects remained on plan with India startup expected in the first quarter of 2028, and adjusted diluted EPS increased 7% to $2.39.

Crown Holdings, Inc. engages in the design, manufacture, and sale of packaging products and equipment for consumer goods. The firm offers aerosol cans, beverage, promotional, and transit packaging, closures and capping, and food cans. It operates through the following segments: Americas Beverage, European Beverage, Asia Pacific, Transit Packaging, and Other. The Americas Beverage segment manufactures beverages, food and aerosol cans and ends, glass bottles, specialty packaging, metal vacuum closures, steel crowns, and aluminum caps. The Europe Beverage segment operates in Europe, the Middle East, and North Africa. The Asia Pacific segment includes beverage and non-beverage can operations. The Transit Packaging segment offers industrial and protective solutions and is involved in the equipment and tools businesses. The Other segment include the company's food can, aerosol can and closures businesses in North America, and beverage tooling and equipment operations in the U.S. and the United Kingdom. The company was founded by William Painter in 1892 and is headquartered in Tampa, FL.

Crown Holdings, Inc.

Why Did CVS, URGN, CCK Stocks Hit 52-Week Highs Today? 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>CVS Health reached a four-year high of $110.62 ahead of Q2 earnings, driven by retail upgrades and new healthcare services.&nbsp;</li><li>UroGen Pharma hit a seven-year high of $43.92 after Guggenheim raised its price target, citing prescription growth and stronger commercial prospects.&nbsp;</li><li>Crown Holdings hit a four-year high of $121.76 after strong Q2 results, driven by higher beverage can demand.&nbsp;</li></ul>CVS Health (CVS), UroGen Pharma (URGN), and Crown Holdings (CCK) stocks climbed to 52-week highs on Tuesday as investors focused on operational improvements, commercial progress, and earnings optimism.CVS Health and Crown Holdings stocks ended the session 2% higher, while UroGen Pharma gained over 6%.&nbsp;<h2 class="st-heading-2">CVS Expands Healthcare Retail Strategy</h2><a href="https://stocktwits.com/symbol/CVS">CVS Health stock</a> reached a four-year high of $110.62 on Tuesday ahead of its fiscal second-quarter (Q2) earnings announcement scheduled for August 5, as the company is working to modernize its retail footprint while developing higher-margin healthcare offerings.According to Fiscal AI data, analysts expect Q2 revenue of $100.7 billion with earnings of $1.84 per share.&nbsp;The company last week introduced its first pharmacy-centered concept store in Houston, reflecting a move toward more efficient layouts designed around patient care. CVS has also entered the pet prescription market by making animal medications available through its pharmacy locations, opening another revenue channel within its retail network.On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘neutral’ territory the previous day.&nbsp;<h2 class="st-heading-2">UroGen Pharma Gains From Patent Protection</h2><a href="https://stocktwits.com/symbol/URGN">UroGen Pharma stock</a> surged to a seven-year high of $43.92 as Guggenheim increased its price target for URGN to $42 from $32 while maintaining a ‘Buy’ rating. The firm pointed to prescription growth, recent business developments, and improving commercial expectations.The company has strengthened its long-term commercial outlook after receiving a U.S. Patent Allowance expected to protect ZUSDURI (FDA-approved, non-surgical treatment for adults with recurring low-grade bladder cancer) and its investigational treatment UGN-103 through July 2044.&nbsp;Retail sentiment around the stock remained in ‘Neutral’ territory.&nbsp;<h2 class="st-heading-2">Crown Holdings Benefits From Beverage Demand</h2><a href="https://stocktwits.com/symbol/CCK">Crown Holdings stock</a> reached a four-year high of $121.76 after a strong Q2 performance, helped by a 5% increase in global beverage can volumes. The company raised its full-year adjusted earnings outlook to $8.30 to $8.50, from its previous forecast of $7.90 to $8.30.Crown also anticipates adjusted free cash flow of at least $900 million. Mizuho lifted its price target on Crown Holdings to $135 from $130 following the results. Retail sentiment around the stock turned to ‘bullish’ from ‘extremely bullish’ territory the previous day.&nbsp;So far this year, CCK and CVS stocks have gained 14% and 31% respectively, while URGN stock has surged 86%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nok-stock-rises-overnight-retail-bulls-charged-after-smci-s-backlog-surge-call-nokia-pillar-of-infrastructure-ahead-of-earnings/cZZmGS6R7w5">NOK Stock Rises Overnight: Retail Bulls Charged After SMCI's Backlog Surge, Call Nokia 'Pillar Of Infrastructure' Ahead Of Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CVS Health managed to beat analyst expectations on earnings but revenue fell short of estimates.

CVS Health (CVS), UroGen Pharma (URGN), and Crown Holdings (CCK) stocks climbed to 52-week highs on Tuesday as investors focused on operational improvements, commercial progress, and earnings optimism.

Investors showed confidence in healthcare improvements, strong biotech patents, and rising packaging demand. 


Current Price	$121.95
Prev Close	$124.43
Open	$125.00
Dividend Yield	1.01%
50-Day Moving Average	$112.99
Beta	0.53
Avg. Volume	854,465.58
PE Ratio	17.38

52-Week High	$124.89
52-Week Low	$91.31
Market Capitalization	$13.48B
EPS (Annual)	$6.38
Price to Book	4.59
Revenue Per Employee	$537,869.56

Feed

News

Sentiment

Earnings

Fundamentals

Info

CCK Fundamentals